Drug Commonly Used to Treat Bi-Polar Disorder Dramatically Increases Lifespan in Nematode Worms
News Nov 06, 2007
Nematode worms treated with lithium show a 46 percent increase in lifespan, raising the tantalizing question of whether humans taking the mood affecting drug are also taking an anti-aging medication. Results of the Buck Institute study, led by faculty member Gordon J. Lithgow, PhD, are currently published online in the Journal of Biological Chemistry.
Lithium has been used to treat mood affective disorders, including bipolar disease for decades. While the drug has been shown to protect neurons, the underlying mechanism of its therapeutic action is not understood. In humans, lithium’s therapeutic range is very limited and the drug has serious side effects.
The research provides a novel genetic approach to understanding how lithium works and highlights the utility of using the nematode C. elegans as a research subject in the field of “pharmacogenetics”. Pharmocogenetics involves the study of genetic factors that influence an organism’s reaction to a drug.
In the study, scientists discovered that longevity was increased in the worms when the lithium “turned down” the activity of a gene that modulates the basic structure of chromosomes.
Lithgow believes that lithium impacts many genes. “Understanding the genetic impact of lithium may allow us to engineer a therapy that has the same lifespan extending benefits,” said Lithgow. “One of the larger questions is whether the lifespan extending benefits of the drug are directly related to the fact that lithium protects neurons.”
The process of normal aging in humans is intrinsically linked to the onset of neurodegenerative disease. However, the cellular changes and events due to aging that impact neurodegeneration are not yet understood said Lithgow. Studies involving compounds such as lithium could provide breakthroughs in the attempt to understand the biomedical link between aging and disease. Lithgow and his lab are now surveying tens of thousands of compounds for affects on aging.
The study highlights the efficacy of using C. elegans as a new way of studying drug toxicity and genetic impacts of compounds currently in drug development or already in use in humans. “The use of simple model organisms with well developed genetic tools can speed the identification of molecular targets,” said Lithgow. “This could facilitate the development of improved therapies for diseases.”
The paper can be accessed at http://www.jbc.org/cgi/content/abstract/M705028200v1
"Non-Gene" Mutations May Hold Answers to Neurodevelopmental DisordersNews
Mutations in non-coding regions of the genome, which don't contain genes, but control the regulation of other genes, may hold answers to rare developmental disorders that affect the nervous system.READ MORE
Majority of European Wolves Have Dog DNANews
The wolf may not often act like man's best friend, but a new study has found that the majority of wild wolves in Europe contain chunks of dog DNA. The finding is causing scientists to rethink what constitutes a wolfdog hybrid and how we approach conservation of keystone wolf populations.READ MORE
Neuroblastoma Biomarker Research Advances TreatmentNews
Neuroblastoma, a childhood cancer, is treatable in less than half of aggressive cases, but new RNA biomarkers may help identify high-risk patients faster and lead to better prognosis.READ MORE